FTY720 Composition Reduces Alpha-Synuclein Aggregation in Parkinson's Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Parkinson's Disease do not effectively address the progression and symptoms of the condition, particularly motor symptoms, and there is a need for a method that can prevent or delay the onset of these symptoms.
Innovation Solution
Administration of a FTY720 composition, specifically 2-amino-2-[2-(4-octylphenyl)ethyl]-1,3-propanediol, either in its free form or as a pharmaceutically acceptable salt, orally co-administered with active agents like immunosuppressants, corticosteroids, or immunoglobulins, to treat, alleviate, or delay the progression of Parkinson's Disease symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for Parkinson's Disease are used, then motor symptoms are managed, but the progression and onset of symptoms cannot be prevented or delayed
Solution Approach 1:
The patent applies preliminary action by administering FTY720 composition before the onset of motor symptoms to prevent disease progression. The treatment is given in the early stages of Parkinson's disease to delay symptom development, rather than waiting for symptoms to manifest. This proactive approach allows the medication to prevent neuronal damage before it occurs, thereby extending the time before motor symptoms appear.
2Reliability
If FTY720 composition is administered orally, then treatment effectiveness is improved, but alpha-synuclein aggregation continues to progress without intervention
Solution Approach 1:
The patent converts the harmful effect of alpha-synuclein aggregation into a beneficial outcome by using FTY720 composition to target and reduce this aggregation. The medication transforms the pathological process into a therapeutic opportunity, where the presence of alpha-synuclein aggregates serves as a marker for targeted intervention. By specifically addressing the aggregation through FTY720 administration, the treatment turns the harmful accumulation into a focal point for effective therapeutic action.
Data Source
AI summary
The present invention provides a method for treating, alleviating, reversing or delaying progression of at least one symptom of Parkinson's Disease in a subject in need thereof by administering to the subject an effective amount of a 2-amino-2[2-(4-octylphenyl)ethyl]propane-1,3-diol composition or a derivative thereof to treat at least one symptom of Parkinson's Disease.